Yoshitaka Iwanaga

National Cerebral and Cardiovascular Center
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Background Catheter ablation of atrial fibrillation (AF) is an effective treatment to achieve left atrial (LA) and left ventricular (LV) reverse remodeling in patients with systolic dysfunction. However, the relationship between LA and LV reverse remodeling (LARR and LVRR) and their clinical implications remains unclear. Methods Among 5287 consecutive patients undergoing first‐time AF ablation, 620 with baseline LV ejection fraction <50% were evaluated. They underwent multidetector computed tomography at baseline and 3 months after ablation. LARR and LVRR were defined as ≥15% reductions in the LA and LV end‐systolic volume, respectively. The relationship between LARR and LVRR and their impact on clinical outcomes was investigated. Results AF ablation reduced the LA and LV end‐systolic volumes, with reduction rates of 24%±16% and 39%±24%, respectively (r=0.54, P <0.001). During a follow‐up of 50.4 months, patients with LARR−/LVRR− (n=86) showed the highest incidence of AF recurrence (50.0%) and composite of heart failure hospitalization or cardiovascular death (25.6%). Patients with LARR+/LVRR− (n=43) exhibited similar AF recurrence but the second highest incidence of the composite outcomes (16.3%) compared with those with LARR−/LVRR+ (n=95) and LARR+/LVRR+ (n=396). Age‐ and sex‐adjusted Cox regression analysis revealed that LARR−/LVRR− alone was associated with AF recurrence (hazard ratio [HR], 2.01 [95% CI, 1.42–2.85], P <0.001), whereas LARR−/LVRR− (HR, 6.73 [95% CI, 3.48–13.0]) and LARR+/LVRR− (HR, 4.58 [95% CI, 1.86–11.3]) were associated with the composite end point. Conclusions LARR and LVRR were moderately correlated after AF ablation in patients with systolic dysfunction. Their combined assessment delineated distinct postablation trajectories and may improve individual risk stratification.

Year:

2026

Year:

2025

Aims Although the impact of underweight and dementia on mortality is clear, no large study has examined the synergistic impact of underweight and dementia on acute myocardial infarction (AMI) in real-world settings. Therefore, this study aimed to investigate the synergistic effects of underweight and dementia on in-hospital mortality in AMI patients using a nationwide administrative database. Methods and results This nationwide retrospective cohort study was performed using the Japanese nationwide administrative data (Japanese Registry of All Cardiac and Vascular Diseases-Diagnosis Procedure Combination) of 474 979 AMI patients between April 2012 and March 2021. Of these patients, 424 500 with AMI were divided into four groups according to body mass index (<18.5 kg/m² or ≥18.5 kg/m²) and dementia status (presence or absence). We investigated the association of underweight and dementia with in-hospital mortality. In-hospital mortality was highest in the underweight/dementia group (17.5%), followed by the non-underweight/dementia group (13.2%), the underweight/non-dementia group (11.6%), and lowest in the non-underweight/non-dementia group (5.0%). Multilevel mixed-effects logistic regression analysis with multiple imputation and complete cases showed underweight and dementia to be associated alone and in combination with an increased risk of in-hospital mortality. In the subgroup analysis of age categories (<75 years vs. ≥75 years), the synergistic effects of underweight and dementia on in-hospital mortality for AMI were greater for those <75 years of age. Conclusion This nationwide study suggested that the coexistence of underweight and dementia significantly increases the risk of in-hospital mortality in AMI patients and especially younger patients. Early detection and management of both conditions may be crucial for improving survival in this population.

Year:

2025

Clinical evidence of oral inotrope use for advanced heart failure (HF) is limited. This study investigated the contemporary use and association of oral inotropes with prognosis in the outpatient treatment of advanced HF using a nationwide administrative claims database in Japan. Patients hospitalized with acute HF between 2014 and 2021 were identified from the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Associations of the drug use after discharge with the 2‐year prognosis were examined in a propensity‐matching cohort, and hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Of the 428,650 patients discharged with HF in 4433 hospitals, 14,374 (3.4%) had taken oral inotropes, most of whom (95.0%) took pimobendan. Patients taking oral inotropes were younger and more likely to receive HF drugs. Cardiomyopathy as the etiology and the use of intravenous inotropes during hospitalization were more frequently observed. In the 2‐year prognosis, oral inotrope use was associated with higher all‐cause mortality and HF rehospitalization rates (HR [95% CI]: 1.59 [1.51, 1.66] and 1.54 [1.48, 1.61], respectively). Concomitant use of pimobendan and β‐blockers was associated with lower mortality and HF rehospitalization (0.81 [0.74, 0.88] and 0.85 [0.79, 0.92], respectively) compared with pimobendan without β‐blockers. Although no association was found between oral inotrope use and favorable prognosis, concomitant use of β‐blockers may be a better strategy for oral inotrope use in advanced HF.

Year:

2025

Background Transcatheter aortic valve replacement (TAVR) is increasingly used in patients with aortic stenosis; however, the optimal postoperative anticoagulation therapy for patients with atrial fibrillation (AF) remains controversial. We aimed to investigate the association between anticoagulant therapy selection and outcomes in patients with AF after TAVR. Methods We retrospectively analyzed patients with AF who underwent TAVR. Patients were divided into 2 groups according to the anticoagulant therapy administered 3 months after the index TAVR (direct oral anticoagulant [DOAC] and vitamin K antagonist [VKA] groups). The primary end points were thromboembolic and major bleeding events after a landmark period of 3 months. We analyzed the association between oral anticoagulants and outcomes using propensity score matching. Results Among 47 883 patients who underwent TAVR between April 2014 and March 2021, 10 041 had a history of AF and anticoagulant therapy. Of these, 8191 patients were prescribed a DOAC, while 1850 received a VKA. Before matching, the thromboembolic event rate was 2.2 per 100 person‐years in the DOAC group and 3.6 per 100 person‐years in the VKA group, whereas the bleeding event rates were 7.1 and 10.0 per 100 person‐years, respectively. After matching, VKA was associated with higher risks of thromboembolic events (hazard ratio [HR], 1.46 [95% CI, 1.12–1.91]; P =0.004) and bleeding events (HR, 1.21 [95% CI, 1.03–1.42]; P =0.016). Conclusions DOAC use in patients with AF who undergo TAVR may be preferable to VKA use in a real‐world clinical setting.

Year:

2025

Evidence of the effectiveness of β‐blockers in heart failure (HF) and atrial fibrillation (AF) in a contemporary cohort is controversial. This study investigated the association between the use of β‐blockers and prognosis in hospitalized HF patients with and without AF in Japan. Patients hospitalized with the first episode of acute HF were identified from the National Database of Health Insurance Claims and Specific Health Checkups of Japan between April 2014 and March 2021. Associations of β‐blocker use and prognosis were compared by propensity score matching among the AF or non‐AF group. A mixed‐effects survival model was used, and hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Among 428,650 patients discharged with HF in 4,433 hospitals, 175,174 (40.9%) were ≥ 85 years old, 151,873 (35.4%) had complicated AF, and 236,457 (55.2%) were β‐blocker users. In a matched AF group, β‐blocker use was associated with a lower composite outcome of all‐cause mortality or HF rehospitalization (HR [95% CI], 0.95 [0.93–0.97]). A similar result was obtained in a matched non‐AF group (0.95 [0.94–0.96]). In addition, the HRs in patients aged ≥ 85 years and female patients were 1.00 [0.98–1.02] and 1.01 [0.98–1.03] in the AF group and 1.03 [1.01–1.05] and 0.98 [0.97–1.00] in the non‐AF group, respectively. The favorable prognostic associations of β‐blocker use were observed regardless of AF in patients across a broad spectrum of HF in a superaged society.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (13)

Yasushi Sakata

Professor

Osaka University Graduate School of Medicine

JAPAN
View details

Shunsuke Tamaki

Ehime University

JAPAN
View details

Ken-ichi Hirano

Professor

Osaka University

JAPAN
View details

Koshiro Kanaoka

Nara Medical University

JAPAN
View details

Takuo Emoto

Kobe University

JAPAN
View details

Tetsuhisa Kitamura

Osaka University

JAPAN
View details

Yoshihiro Miyamoto

Director General

National Cerebral and Cardiovascular Center

JAPAN
View details

Seiji Takatsuki

Keio University School of Medicine

JAPAN
View details

Shungo Hikoso

Nara Medical University

JAPAN
View details

Tomoya Yamashita

Professor

Kobe University

JAPAN
View details

Akito Nakagawa

invited lecturer

Osaka University Graduate School of Medicine

JAPAN
View details

Kazuhiro P. Izawa

Kobe University

JAPAN
View details

Tetsuo Sasano

-

JAPAN
View details